

# Marilena Cesari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7901771/publications.pdf>

Version: 2024-02-01

35  
papers

1,317  
citations

393982

19  
h-index

377514

34  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1513  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS <sup>2</sup> ). <i>Cancer</i> , 2022, 128, 1958-1966.	2.0	12
2	Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2617-2624.	2.0	45
3	Long-Term Follow-up of a Randomized Study of Oral Etoposide versus <i>Viscum album</i> Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. <i>Sarcoma</i> , 2020, 2020, 1-9.	0.7	5
4	Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27792.	0.8	19
5	Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27653.	0.8	19
6	Pazopanib in relapsed osteosarcoma patients: report on 15 cases. <i>Acta Oncologica</i> , 2019, 58, 124-128.	0.8	50
7	Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 591-599.	1.3	8
8	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. <i>Tumori</i> , 2018, 104, 30-36.	0.6	84
9	Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. <i>Acta Oncologica</i> , 2018, 57, 958-964.	0.8	41
10	Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. <i>Tumori</i> , 2018, 104, 202-206.	0.6	14
11	Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results. <i>Tumori</i> , 2018, 104, 344-351.	0.6	41
12	Osteosarcoma follow-up: chest X-ray or computed tomography?. <i>Clinical Sarcoma Research</i> , 2017, 7, 3.	2.3	17
13	Survival after Second and Subsequent Recurrences in Osteosarcoma: A Retrospective Multicenter Analysis. <i>Tumori</i> , 2017, , tj.5000636.	0.6	7
14	Ewing Sarcoma in Patients over 40 Years of Age: A Prospective Analysis of 31 Patients Treated at a Single Institution. <i>Tumori</i> , 2016, 102, 481-487.	0.6	13
15	Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. <i>BMC Cancer</i> , 2016, 16, 280.	1.1	71
16	Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. <i>European Journal of Cancer</i> , 2015, 51, 374-381.	1.3	133
17	Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age. <i>Journal of Chemotherapy</i> , 2014, 26, 49-56.	0.7	10
18	Primary Angiosarcoma of Bone. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 528-534.	0.6	34

#	ARTICLE	IF	CITATIONS
19	Analysis of Risk Factors for Central Venous Catheter-Related Complications. <i>Cancer Nursing</i> , 2014, 37, 292-298.	0.7	6
20	Periosteal osteosarcoma. <i>Cancer</i> , 2011, 117, 1731-1735.	2.0	60
21	Vincristine, Doxorubicin, Cyclophosphamide, Actinomycin D, Ifosfamide, and Etoposide in Adult and Pediatric Patients with Nonmetastatic Ewing Sarcoma. Final Results of a Monoinstitutional Study. <i>Tumori</i> , 2010, 96, 213-218.	0.6	15
22	Sex- and Age-Related Chemotherapy Toxicity in Patients with Non-Metastatic Osteosarcoma. <i>Journal of Chemotherapy</i> , 2009, 21, 205-210.	0.7	25
23	Mesenchymal Chondrosarcoma. An Analysis of Patients Treated at a Single Institution. <i>Tumori</i> , 2007, 93, 423-427.	0.6	106
24	Predictive Factors of Histologic Response to Primary Chemotherapy in Patients With Ewing Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 364-368.	0.3	29
25	Late Relapse in Osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 418-422.	0.3	32
26	Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy. <i>Cancer</i> , 2006, 106, 2701-2706.	2.0	61
27	Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate. <i>Anti-Cancer Drugs</i> , 2005, 16, 733-738.	0.7	20
28	Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). <i>Annals of Oncology</i> , 2003, 14, 1365-1372.	0.6	25
29	Predictive factors for local recurrence in osteosarcoma 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. <i>Acta Orthopaedica</i> , 1998, 69, 230-236.	1.4	134
30	Neoadjuvant Chemotherapy for Extremity Osteosarcoma: Preliminary Results of the Rizzoli's 4th Study. <i>Acta Oncologica</i> , 1998, 37, 41-48.	0.8	78
31	Predictive Factors of Histological Response to Primary Chemotherapy in Ewing's Sarcoma. <i>Acta Oncologica</i> , 1998, 37, 671-676.	0.8	19
32	Osteosarcoma of the Extremities with Synchronous Lung Metastases: Long-Term Results in 44 Patients Treated with Neoadjuvant Chemotherapy. <i>Journal of Chemotherapy</i> , 1998, 10, 69-76.	0.7	39
33	Ifosfamide and Actinomycin-D, Added in the Induction Phase to Vincristine, Cyclophosphamide and Doxorubicin, Improve Histologic Response and Prognosis in Patients with Non Metastatic Ewing's Sarcoma of the Extremity. <i>Journal of Chemotherapy</i> , 1998, 10, 484-491.	0.7	28
34	Neoadjuvant Chemotherapy for Osseous Malignant Fibrous Histiocytoma of the Extremity: Results in 18 Cases and Comparison with 112 Contemporary Osteosarcoma Patients Treated with the Same Chemotherapy Regimen. <i>Journal of Chemotherapy</i> , 1997, 9, 293-299.	0.7	17
35	Osteonecrosis of the jaw (ONJ) after denosumab in patients with giant cell tumor of bone (GCTB): a single institution analysis of a prospective, international study 2006-2014. <i>Qeios</i> , 0, , .	0.0	0